Engineered RBCs for Cancer Vaccines
Oncology
Key Facts
About Portal Biotechnologies
Portal Biotechnologies is a private, platform technology company pioneering a novel physical method for intracellular delivery called 'Cell Squeeze®'. This technology enables the delivery of a wide range of cargo (proteins, nucleic acids, CRISPR components) into virtually any cell type, including hard-to-transfect primary immune cells, with high efficiency and viability. The company has rapidly gained traction with over 50 biopharma and academic partners, secured significant non-dilutive funding from DARPA, and completed an oversubscribed seed round. Portal's strategy involves selling research instruments (Gateway, Galaxy) to drive platform adoption while developing its own therapeutic programs and partnerships in cell therapy and immuno-oncology.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |